Royalty Pharma (RPRX) EBT Margin Growth (3y) (2022 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EBT Margin Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 6,691.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2,054.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8,006.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 9,980.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -5,319.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 31,363.00 |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 1,581.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,319.00 |
| Mar 31, 2026 | -17.00 |
| Dec 31, 2025 | 16,505.00 |
| Sep 30, 2025 | 3,447.00 |
| Jun 30, 2025 | -7,572.00 |
| Mar 31, 2025 | 5,366.00 |
| Dec 31, 2024 | 4,700.00 |
| Sep 30, 2024 | 10,493.00 |
| Jun 30, 2024 | -10,919.00 |
| Mar 31, 2024 | -2,850.00 |
| Dec 31, 2023 | 5,631.00 |
| Sep 30, 2023 | -9,318.00 |
| Jun 30, 2023 | -5,254.00 |
| Mar 31, 2023 | 5,265.00 |
| Dec 31, 2022 | -42,402.00 |
| Sep 30, 2022 | -5,634.00 |
| Jun 30, 2022 | 5,266.00 |